News

Sanofi India Q4: Declares final dividend of ₹48; PAT surges 50%, revenue up 47%Sanofi India Q4 Results | The final dividend is in addition to the interim dividend of ₹75 declared on October 29, 2025. The total dividend for 2025 will amount to ₹123/share. Shares of Sanofi India Ltd ended at ₹4,142.80, up by ₹65.20, or 1.60%, on the BSE today, February 25.By Jomy Jos Pullokaran  February 25, 2026, 7:56:58 PM IST (Published)2 Min ReadDrug firm Sanofi India Ltd on Wednesday (February 25) announced that its board of directors has recommended a final dividend of ₹48 per equity share of face value ₹10 for the financial year ended December 31, 2025.

This final dividend is subject to shareholder approval at the 70th annual general meeting and is in addition to the interim dividend of ₹75 per share declared on October 29, 2025. The total dividend for 2025 will amount to ₹123 per equity share.

Fourth quarter results

For Q4, the company posted revenue of ₹251 crore, a growth of 47% year-on-year. Domestic sales grew 23%, aided by the relaunch of recalled products, while export sales surged 9.3 times due to a low base. Profit after tax for the quarter rose 50% to ₹66.5 crore.

Also Read: Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Full year figures

For the full year 2025, Sanofi Consumer Healthcare India reported revenue of ₹878.4 crore, up 21% from the previous year. Domestic sales increased 7%, and export sales rose 158% on a low base. Profit after tax for the year stood at ₹240.1 crore, up 33% year-on-year, supported by disciplined cost management and an improved product mix.

Top level changes

The board also approved changes in its leadership. Rajani Kesari has been appointed as an additional and independent director for a term of five years, effective April 1, 2026, subject to shareholder approval.

Rodolfo Hrosz has tendered his resignation as non-executive director effective February 28, 2026, due to other commitments. The board recorded its appreciation for Hrosz's contributions during his tenure.

Also Read: Sanofi India Q3 Results: Profit and revenue decline, declares ₹75 interim dividend

Sudipta Chakraborty has been appointed as an additional director and whole-time director for a term of three years, effective March 1, 2026. She will also serve as key managerial personnel and senior management personnel of the company, subject to shareholder approval.

Shares of Sanofi India Ltd ended at ₹4,142.80, up by ₹65.20, or 1.60%, on the BSE today, February 25.

Continue Reading(Edited by : Shoma Bhattacharjee)TagsearningsResults BoardroomSanofi Indiashare market today